An Open Protocol for the Compassionate Use of Thalidomide
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00081757|
Recruitment Status : Completed
First Posted : April 22, 2004
Last Update Posted : July 2, 2010
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Thalidomide||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||250 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Protocol For The Compassionate Use of Thalidomide For Patients With Advanced Or Refractory Malignancies|
|Study Start Date :||September 1998|
|Estimated Study Completion Date :||May 2005|
- The primary objective of this study is to use thalidomide to treat patients with advanced and/or refractory malignancies as part of a defined treatment protocol.
- The secondary objective of this study is to collect further basic safety and efficacy data.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00081757
|United States, Arkansas|
|University of Arkansas for Medical Sciences/MIRT|
|Little Rock, Arkansas, United States, 72205|
|Principal Investigator:||Athanasios Fassas, MD||UAMS|